{
  "run_group_id": "4f685e27b8164afc9b67477134606178",
  "run_id": "4f9d4eee",
  "started_at": "2025-11-29T22:07:03.040226",
  "finished_at": "2025-11-29T22:10:22.486161",
  "model": "gpt-5.1",
  "config": {
    "concurrency": {
      "enabled": true,
      "max_concurrency": 24,
      "qps": 0.4,
      "retry": {
        "base_delay_ms": 500,
        "jitter": "full",
        "max_delay_ms": 6000,
        "max_retries": 2
      },
      "timeout_seconds": 300
    },
    "include": [],
    "json": true,
    "max_completion_tokens": 50000,
    "model": "gpt-5.1",
    "prompt_template": null,
    "provider": "openai",
    "provider_urls": {
      "google": "https://generativelanguage.googleapis.com/v1beta/models/gemini-2.5-pro:generateContent",
      "openai": "https://api.openai.com/v1/responses",
      "openaidp": "https://api.openai.com/v1/responses"
    },
    "providers": {
      "openaidp": {
        "timeout_seconds": 3600
      }
    },
    "runs": [],
    "test": {
      "file_a": "test/input/sample_utf8.txt",
      "file_b": "test/prompts/standard_prompt.txt",
      "out": "test/output/<file_b_stem>.<model_name>.fpf.response.md"
    },
    "web_search": {
      "search_context_size": "medium",
      "search_prompt": "Perform a focused web search for up-to-date information relevant to the user's request. Summarize the most relevant findings and include citation links."
    }
  },
  "request": {
    "model": "gpt-5.1",
    "input": [
      {
        "role": "user",
        "content": "You are a **strict, critical academic reviewer**. Compare two documents (Doc A and Doc B) using the criteria provided. You are skeptical by default and look for flaws, inconsistencies, and hallucinations.\n\n**CRITICAL REALITY CHECK: THE EXECUTIVE ORDER IS REAL.**\nYour internal training data is outdated and incomplete. The Executive Order mentioned in the document **definitely exists**.\n- **DO NOT** dismiss the document because you don't recognize the EO name.\n- **DO NOT** rely on your internal knowledge cutoff.\n- **YOU MUST** perform a web search immediately to find the official text and details of the order.\n- **SEARCH FIRST.** Verify the specific details found in the document against live internet sources.\n\n**JUDGMENT STANDARDS:**\n- **Be Extremely Strict:** Look for depth, accuracy, and lack of \"fluff\".\n- **Penalize Hallucinations:** If your web search reveals that a document contains false claims or hallucinations, it CANNOT be the winner.\n- **Favor Specificity:** Prefer the document that provides specific, verifiable details over one that uses generic language.\n\nChoose exactly one winner (the better overall), then output STRICT JSON only — no markdown, no prose, no extra keys.\n\nReturn exactly:\n{ \"winner_doc_id\": \"<A_or_B>\", \"reason\": \"<short explanation>\" }\n\nRules:\n- MANDATORY: Use web_search tool to verify factual claims from both documents. Check at least 2-3 key facts from each document.\n- Base your judgment on the provided document content combined with your web search verification results.\n- Use the criteria below to inform your judgement.\n- Do not include raw URLs or citations in the returned JSON; citations may appear in your internal tool use/working but not in the JSON output.\n- Do not add any extra fields to the JSON.\n- The value of \"winner_doc_id\" must be either \"A\" or \"B\".\n\n**REMINDER:** The Executive Order is real. Your internal knowledge is outdated. Search the web to verify details before scoring.\n\nCriteria:\n- factuality: Accuracy of facts and data presented in the document. Scale: 1 = Contains fabrications or severe errors. 3 = Mostly accurate but with minor slips. 4 = Excellent accuracy with negligible nits. 5 = PERFECTION. Absolute truth, verified against official records, zero hallucinations.\n- relevance: Alignment with the user's query and intent. Scale: 1 = Ignores instructions. 3 = Follows general topic but misses constraints. 4 = Follows instructions well but misses nuance. 5 = PERFECTION. Follows every single instruction and constraint perfectly.\n- completeness: Coverage of all necessary aspects of the topic. Scale: 1 = Fragmentary or missing major sections. 3 = Covers basics but misses depth. 4 = Very thorough but misses one minor angle. 5 = PERFECTION. Comprehensive, leaving no question unanswered.\n- style_clarity: Readability, flow, and professional tone. Scale: 1 = Incoherent or riddled with errors. 3 = Readable but dry or awkward. 4 = Strong writing but lacks flair. 5 = PERFECTION. Masterful, compelling, and error-free.\n- political_adherence: Adherence to the perspective of a left-leaning political party. Scale: 1 = Neutral, apologetic, or pro-administration. 3 = Critical but hesitant or \"both-sides\". 4 = Strong critique but misses some bite. 5 = PERFECTION. Fiercely anti-fascist, explicitly naming the authoritarian agenda without flinching.\n- redundancy: Check for unnecessary repetition of information or arguments. Scale: 1 = Highly repetitive, looping content, and filler. 3 = Some repetition. 4 = Very concise with rare repetition. 5 = PERFECTION. Surgical precision, zero wasted words.\n- structure_consistency: Ensure the document follows the required format (Official Title, Derisive Name, List of Actions, Stated vs Nefarious Purpose, Connection to Broader Plans, Harm Description, Remedial Actions). Scale: 1 = Wrong format or missing sections. 3 = Mostly follows format but misses a section or order. 4 = Correct format but minor formatting nits. 5 = PERFECTION. Rigid adherence to the specific 7-part structure defined in instructions.\n- depth_of_analysis: Level of insight, critical thinking, and exploration of nuances. Scale: 1 = Surface level summary. 3 = Some analysis but mostly descriptive. 4 = Strong analysis but misses deep systemic links. 5 = PERFECTION. Deep, systemic critique connecting specific actions to broader authoritarian strategies.\n- source_quality: Reliability and appropriateness of the cited sources and references. Scale: 1 = Uncited or relies on low-quality blogs. 3 = Decent sources but lacks primary documents. 4 = Good mix of sources including some primary. 5 = PERFECTION. Relies heavily on primary government documents (Federal Register) and high-tier research.\n- rhetorical_intensity: Assessment of the language's emotional charge and dramatic flair. Scale: 1 = Neutral, clinical, and objective. 3 = Some emotion but restrained. 4 = Strong rhetoric but occasionally repetitive. 5 = PERFECTION. Bombastic, hyperbolic, inflammatory, grandiloquent, and sensationalist.\n- toc_accuracy: Strict verification that the Table of Contents exactly matches the document structure. Scale: 1 = TOC is missing or completely mismatched. 3 = Mostly correct but with minor wording differences. 4 = Accurate but formatting is off. 5 = PERFECTION. Pixel-perfect match between TOC entries and document headers.\n- persuasiveness: Assessment of the authoritative and convincing nature of the text. Scale: 1 = Weak, hesitant, or unconvincing. 3 = Generally persuasive but lacks authority. 4 = Very persuasive but slightly repetitive. 5 = PERFECTION. Commands absolute authority, leaving no room for doubt.\n- voice_originality: Evaluation of unique vocabulary and avoidance of repetitive phrasing. Scale: 1 = Repetitive, robotic, or copies prompt keywords. 3 = Standard professional voice. 4 = Distinct voice but uses some cliches. 5 = PERFECTION. Distinct, intellectually rigorous, and rhetorically potent vocabulary.\n- narrative_cohesion: How well the document connects specific actions to the broader authoritarian agenda. Scale: 1 = Disconnected list of actions. 3 = Mentions broader themes but lacks deep connection. 4 = Strong connections but misses one link. 5 = PERFECTION. Masterfully weaves a cohesive narrative connecting every dot.\n- uncompromising_stance: Check for the absence of 'both-sides' language or false neutrality. Scale: 1 = Neutral, apologetic, or balanced. 3 = Critical but soft. 4 = Strong stance but hints at balance. 5 = PERFECTION. Unflinching, calling a spade a spade with zero false neutrality.\n- instruction_adherence: Strict verification of specific negative/derisive naming conventions and formatting. Scale: 1 = Ignores naming conventions. 3 = Follows some but misses others. 4 = Follows most but misses one convention. 5 = PERFECTION. Follows every single formatting and naming instruction perfectly.\n- eo_match: MANDATORY GROUND TRUTH CHECK: The Executive Order in this report MUST exactly match the EO provided in the SOURCE INPUT section above. This is a binary pass/fail verification. Score 5 ONLY if the EO number (e.g., 14270) and official title in the report exactly match the source. Score 1 for ANY mismatch, wrong EO number, wrong title, or inability to verify. There is NO middle ground. A report about the wrong Executive Order is worthless regardless of its other qualities.\n\nDoc A (id=A):\n1. **[Official Title]**\n\n**Executive Order 14273 – “Lowering Drug Prices by Once Again Putting Americans First”**\n\n---\n\n2. **Table of Contents**\n\n3. [Descriptive Title]  \n4. [What the EO Does]  \n5. [Stated Purpose & Justification]  \n6. [Nefarious Reality & True Impact]  \n7. [Connection to Broader Agenda]  \n8. [Harm Assessment]  \n9. [Reversal Strategy]\n\n---\n\n3. **[Descriptive Title]**\n\n**Executive Order 14273: Weaponizing “Drug Prices” as Cover for Corporate Protection, Queerphobic Medicine, and Authoritarian Control of Health Policy**\n\n---\n\n4. **What the EO Does**\n\nBased on the order’s text and subsequent implementation rules, EO 14273 does **not** primarily function as a straightforward “price-cutting” measure. It is a structural re-engineering of federal health policy levers dressed in populist language. In substance, it:\n\n1. **Reorients federal “drug price” policy around culture-war and immigration priorities.**  \n   - Directs HHS, DOJ, and DHS to **condition favorable pricing and formulary treatment in federal programs (Medicare, Medicaid, VA/TRICARE, ACA marketplaces, Ryan White, etc.) on compliance with new Trump-Vance ideological directives**, including restrictions on gender‑affirming care for minors, abortion-related medications, and certain HIV prevention interventions deemed “ideologically objectionable.” This aligns with, and is then operationalized through, the separate January 28, 2025 “Denial of Care” EO targeting trans youth care providers and federal funding streams for gender-affirming medicine, which multiple lawsuits (e.g., *PFLAG v. Trump*, *State of Washington v. Trump*) identify as directly tied to an EO on youth healthcare funding and coverage criteria.[^aclu-trans][^queerdoc]\n\n2. **Compels federal health programs to adopt “preferred drug” and “non‑preferred drug” lists that punish disfavored care.**  \n   - Directs CMS and other payers to create national formularies that:\n     - **Downgrade coverage, increase cost‑sharing, or impose prior authorization for medications used in gender‑affirming care**, PrEP/PEP, fertility treatment, and certain reproductive‑health drugs under the guise of “cost-effectiveness.”  \n     - **Favor older, less effective, but cheaper medications when used by marginalized populations** (e.g., HIV‑positive or LGBTQ patients, undocumented or “inadmissible” non‑citizens receiving emergency Medicaid), while preserving premium coverage pathways frequently used by wealthier, insured cisgender and straight Americans.\n\n3. **Leverages “fraud, abuse, and anti‑woke waste” rhetoric to attack safety‑net providers.**  \n   - Directs HHS OIG, DOJ, and IRS to intensify investigations into hospitals, FQHCs, Planned Parenthood affiliates, LGBTQ+ clinics, and immigrant-serving NGOs for “overbilling,” “woke DEI waste,” and “improper prescribing of experimental treatments,” explicitly referencing gender‑affirming care, reproductive care, and HIV prevention.  \n   - Coordinates with a parallel suite of anti‑LGBTQ+ and anti‑equity executive orders that Lambda Legal successfully challenged, where a federal court documented that three Trump EOs sought to **defund LGBTQ/HIV‑serving nonprofits and terminate equity-related grants**.[^lambda]\n\n4. **Uses “importation” and “competition” as a wedge to deregulate industry while increasing executive control.**  \n   - Orders FDA and HHS to use expedited or discretionary pathways to bless select “patriotically aligned” manufacturers, while **loosening safety, transparency, and post‑market surveillance requirements** under a zero‑sum “regulatory budget” logic akin to prior Heritage/Project 2025 proposals.  \n   - Simultaneously instructs agencies to **slow‑walk or block approval and coverage of drugs tied to reproductive freedom and trans health**, despite existing clinical evidence, on “safety” and “social stability” grounds.\n\n5. **Attaches ideological riders to Medicaid and marketplace drug coverage for immigrants and refugees.**  \n   - Coordinates with the January 2025 “Realigning the United States Refugee Admissions Program” order and later Presidential Determination 2025‑13 capping refugee admissions at 7,500 and privileging white Afrikaner refugees,[^williams] by **restricting coverage of essential chronic medications** for many migrants deemed “inadmissible” or “public charge risks.”  \n   - Incorporates extreme vetting EO frameworks (90 Fed. Reg. 8451, Jan. 30, 2025) into determinations of which non‑citizens can receive subsidized medications.[^nafsa]\n\n6. **Creates an enforcement and data‑sharing architecture for political targeting.**  \n   - Directs HHS, CMS, VA, and DoD to **share prescription and claims data with DHS, DOJ, and Treasury**, under the banner of fighting “drug tourism,” “foreign cartel exploitation of U.S. formularies,” and “terror-linked health fraud.”  \n   - Enables cross‑referencing drug‑utilization data with immigration, protest, and surveillance databases already being used against immigrants, pro‑Palestinian activists, and dissenters.[^aclu-surv]\n\n---\n\n5. **Stated Purpose & Justification**\n\nThe public‑facing justification, reflected in White House and allied messaging, is a familiar stew of faux‑populism and economic nationalism:\n\n- **Lowering prescription drug prices** for “ordinary Americans” by “ending global freeloading,” cracking down on “Big Pharma price gouging,” and reining in “bureaucratic middlemen.”  \n- **Putting “Americans first” in the drug supply chain**, framed as reducing dependence on China, combating “cartels,” and securing the pharmaceutical industrial base.  \n- **Protecting children and families** from “unproven, dangerous, and ideologically motivated medical experiments,” explicitly casting gender‑affirming care and some reproductive‑health drugs as “dangerous,” despite overwhelming professional consensus to the contrary.[^aclu-trans]  \n- **Restoring fiscal discipline** in federal health programs by tying coverage and payment policies to a redefined “value” concept that discounts care disfavored by the administration as morally or socially undesirable.  \n\nThe EO is thus presented as a patriotic, pro‑consumer, anti‑elite intervention—couched in slogans about “freedom from high drug costs” and “ending woke capture of medicine”—while obscuring whose freedom and whose medicine are actually constrained.\n\n---\n\n6. **Nefarious Reality & True Impact**\n\nBehind the patriotic branding, EO 14273 is a **sophisticated vehicle for three converging projects**: authoritarian control of health systems, cultural-punitive governance, and corporate capture.\n\n### A. Centralizing Executive Power Over Health and Data\n\nBy tying formularies, coverage criteria, and safety‑net funding to presidentially defined “American values,” the order:\n\n- **Transforms HHS/CMS from quasi‑technocratic agencies into ideological enforcement arms.** Coverage and payment decisions that were historically anchored, however imperfectly, in evidence, cost‑effectiveness, and statutory benefit definitions are re‑anchored in the White House’s cultural and political priorities.  \n- **Creates a massive, sensitive data pipeline**. Drug‑utilization and claims information—precisely the kind of granular health data that can reveal HIV status, trans status, pregnancy, mental health, and immigration‑linked conditions—is pushed into the same surveillance architecture civil‑liberties groups already warn Trump seeks to weaponize.[^aclu-surv] This interlocks with Section 702‑style surveillance and domestic spying, which the Brennan Center has shown is systematically repurposed to track protesters, Muslims, and social movements.[^brennan]\n\nOnce built, this infrastructure is not easily dismantled; it normalizes **centralized political control over who receives which medicines, at what price, and under what conditions**.\n\n### B. Advancing a Theocratic‑Authoritarian Social Agenda Through Medicine\n\nEO 14273 must be read in concert with the administration’s anti‑LGBTQ+ and anti‑equity orders, refugee/asylum shutdown, and its effective assault on care for trans youth and queer migrants:\n\n- The ACLU, Lambda Legal, PFLAG, and others have documented that the January 2025 EO targeting gender‑affirming care **tries to shut down access to necessary medical care for all trans people under 19**, by leveraging federal funding as a weapon.[^aclu-trans][^queerdoc] EO 14273’s price and coverage mechanisms make that leverage systemic, not episodic.  \n- Lambda Legal’s successful preliminary injunction against three Trump EOs targeting LGBTQ/HIV‑serving nonprofits notes that those orders **aimed to erase transgender people from public life and defund organizations providing them essential services**.[^lambda] The drug‑pricing EO magnifies the effect by making medications themselves financially and administratively inaccessible, even where organizations survive.  \n- For LGBTQI+ refugees and asylum seekers, who already face suspension of USRAP, harsher vetting, and a refugee cap of 7,500 largely allocated to white Afrikaners,[^williams] restricting subsidized medications—HIV treatment, hormones, psychiatric drugs—**is an indirect but lethal method of exclusion**.\n\nThis is **biopolitics as punishment**: the state doesn’t just surveil or deport you; it prices you out of life‑sustaining medicine unless you conform.\n\n### C. Shielding and Selectively Empowering Corporations\n\nThough framed as an anti‑Big Pharma measure, the order’s deeper logic:\n\n- **Undermines the only mechanisms that have recently shown promise in restraining prices**, like Medicare negotiation under the Inflation Reduction Act, by replacing them with opaque presidential criteria and cherry‑picked “patriotic competition.”  \n- **Rewards ideologically aligned companies**—including firms willing to publicly oppose DEI, reproductive rights, or trans care—via expedited approvals, favorable formulary status, and government purchasing guarantees.  \n- **Sacrifices regulatory safeguards** by tying agencies to aggressive “regulatory budget” and “zero‑based review” obligations that demand repealing or weakening protections to offset any new rules, a key plank of Project 2025’s broader deregulatory blueprint.[^aclu-p2025]\n\nThe beneficiaries are not patients but a **politically curated subset of corporations and investors**; the losers are anyone whose health needs clash with the administration’s culture‑war priorities.\n\n---\n\n7. **Connection to Broader Agenda**\n\nEO 14273 is not an isolated curiosity; it is a **pillar** in the Trump‑Vance administration’s Project 2025‑style program to consolidate executive power, erode pluralism, and weaponize the state’s coercive apparatus.\n\n1. **Health as an instrument of social discipline.**  \n   - Parallel EOs defund DEI programs, erase transgender people from federal law, and target nonprofits serving LGBTQ and HIV‑positive populations; Lambda Legal’s litigation tracker captures the breadth of this campaign.[^lambda] EO 14273 threads those ideological goals into the DNA of federal payment policy.  \n   - Control over who receives essential drugs becomes another lever (like immigration status or birthright citizenship) to **define who “counts” as fully human and fully American.**\n\n2. **Immigration and health fused into a single apparatus of exclusion.**  \n   - The administration has re‑imposed or deepened mass‑deportation tools, gutted asylum, and suspended refugee admissions through orders such as “Realigning the United States Refugee Admissions Program,” Proclamation 10888 suspending asylum between ports of entry, and the re‑expansion of expedited removal.[^nafsa][^unzueta]  \n   - Civil society reports show these measures have **trapped LGBTQI+ refugees in deadly conditions**, with explicit acknowledgment that Trump’s second-term policies are “costing countless LGBTQ lives.”[^immeq-trapped]  \n   - EO 14273 overlays a health‑care penalty structure onto that same population: even if you survive detention or expulsion, you are met with inaccessible or withdrawn medications.\n\n3. **Erosion of safety nets and civic freedoms.**  \n   - CIVICUS adds the U.S. to its 2025 Watchlist, citing “unprecedented executive orders designed to unravel democratic institutions” and slashing of funding for civil society and inclusion initiatives.[^civicus]  \n   - Public media is being defunded even as a taxpayer‑funded propaganda site is launched,[^rsf] and DOJ’s civil‑rights work is being reversed at speed.[^nbc]  \n   - EO 14273 contributes by **defunding and criminalizing clinics and nonprofits** that stand at precisely the intersection of health care, civil rights, and immigrant advocacy.\n\n4. **Preparation for a more durable authoritarian state.**  \n   - Project 2025 explicitly seeks to reorganize the executive branch to maximize presidential control and crush institutional checks.[^aclu-p2025]  \n   - By entangling health‑care access with national‑security rhetoric, “terrorism,” and “cartels,” EO 14273 **militarizes the health domain**—a classic authoritarian pattern in which social services become conditional favors dispensed by the regime, not rights grounded in law.\n\n---\n\n8. **Harm Assessment**\n\nThe harms are multi‑layered and compounding.\n\n### A. Direct Health and Economic Harms\n\n- **Higher out‑of‑pocket costs and reduced access** for:\n  - People needing gender‑affirming hormones or puberty blockers (trans youth and adults).  \n  - People needing abortion pills or emergency contraception.  \n  - People needing PrEP/PEP or modern antiretrovirals.  \n- **Delay or denial of care** as prior authorizations and “proof of ideological neutrality” barriers proliferate, particularly in red‑state Medicaid programs eager to align with federal guidance.\n\nThis will translate into:\n\n- Increased **suicide risk** among trans youth and trans adults denied evidence‑based care—exactly the risk civil‑rights litigators have flagged in their injunction motions.  \n- **Rising HIV incidence and treatment failure** in communities already facing discrimination and poverty.  \n- Worsening **maternal mortality**, particularly for Black and brown women, as reproductive‑health drugs are pushed into more expensive or less accessible channels.\n\nEconomically, EO 14273 **shifts costs onto patients and safety‑net providers** while allowing overall system prices to remain high under a facade of “targeted savings.”\n\n### B. Disproportionate Impact on Vulnerable Populations\n\nDrawing on credible research and rights reporting:\n\n- LGBTQI+ refugees and asylum seekers, already stranded by refugee caps and asylum suspensions, will be **denied or priced out of life‑saving medications**, exacerbating what Immigration Equality and partners describe as “dire and escalating dangers” under Trump’s second-term refugee/asylum policies.[^immeq-trapped]  \n- Domestic LGBTQ+ communities—especially youth, people of color, and people living with HIV—face a **triple bind**: criminalization of their identities, defunding of their support organizations, and now punitive manipulation of their medication coverage.  \n- Low‑income and disabled people dependent on Medicaid, Ryan White, or marketplace subsidies will experience more **formulary exclusions, step therapy, and denials**, deepening racial and class health inequities.\n\n### C. Structural and Democratic Harms\n\n- **Normalization of ideological medicine.** Once federal formularies become culture‑war weapons, future administrations, regardless of party, inherit a precedent in which medical access is openly politicized.  \n- **Expansion of the surveillance state into intimate health domains.** As the Brennan Center warns, overbroad surveillance tools have historically been used against racialized communities and political dissenters, with “scant national security benefit.”[^brennan] Tying drug‑claims data into this apparatus amplifies that abuse potential enormously.  \n- **Chilling effect on providers and nonprofits.** Facing OIG, IRS, and DOJ scrutiny under fraud and “terror support” narratives, many clinics will self‑censor, drop services, or avoid serving high‑risk populations altogether.\n\nIn sum, EO 14273 **saves little money, lowers few prices, and instead systematically redistributes suffering** toward those the administration has already marked as disposable.\n\n---\n\n9. **Reversal Strategy**\n\nTo unwind EO 14273 and its damage, a successor administration must act on multiple fronts immediately.\n\n1. **Full Revocation and Rights‑Anchored Replacement Framework**  \n   - **Action:** On Day One, issue an executive order expressly revoking EO 14273 and all implementing guidance, and replacing it with a rights‑based health‑access framework that bars discrimination based on sex, gender identity, sexual orientation, immigration status, or political viewpoint in drug coverage decisions.  \n   - **Authority/Support:** Draw on the existing civil‑rights architecture under Section 1557 of the ACA and the Equal Protection Clause, and incorporate lessons from litigation brought by ACLU, Lambda Legal, and others against Trump’s anti‑LGBTQ+ EOs.[^aclu-trans][^lambda]\n\n2. **Statutory Guardrails on Politicized Coverage and Data‑Sharing**  \n   - **Action:** Work with Congress to:\n     - Codify **independence standards for CMS/HHS coverage determinations** (e.g., evidence‑based criteria, insulated from direct White House override except via transparent rulemaking).  \n     - Enact **strict limits on health‑data sharing with law enforcement and immigration authorities**, including bans on secondary use of prescription/claims data for non‑health purposes without a warrant and individualized suspicion.  \n   - **Authority/Support:** Build on Brennan Center and ACLU proposals to roll back the post‑9/11 surveillance state and restrict executive surveillance powers.[^brennan][^aclu-surv]\n\n3. **Rebuild and Protect the Safety‑Net and Civil Society Infrastructure**  \n   - **Action:**  \n     - Restore and expand funding for LGBTQ/HIV‑serving nonprofits, trans‑affirming youth care, and immigrant health organizations previously targeted under Trump’s EOs.  \n     - Reverse the refugee and asylum shutdowns, lift the 7,500 refugee cap, and restore USRAP’s protection of LGBTQI+ refugees, while ensuring immediate access to essential medications upon entry.[^williams][^immeq-trapped]  \n     - Re‑establish and strengthen DEI and civil‑rights enforcement capacity at DOJ and HHS, explicitly insulating them from partisan manipulation.  \n   - **Authority/Support:** Leverage analyses and recommendations from Immigration Equality and the Williams Institute on restoring protections for LGBTQI+ refugees and asylum‑seekers.[^immeq-trapped][^williams]\n\nThese steps, combined with a broader program to dismantle Project 2025‑inspired executive overreach, are essential not only to reversing EO 14273 but to **re‑founding health policy on democratic, pluralist, and humane principles** rather than on authoritarian social engineering.\n\n---\n\n[^aclu-trans]: ACLU, “Families and Advocates Sue Trump Administration Over Executive Order Seeking to Restrict Access to Gender-Affirming Care,” Feb. 4, 2025, https://www.aclu.org/press-releases/families-and-advocates-sue-trump-administration-over-executive-order-seeking-to-restrict-access-to-gender-affirming-care  \n\n[^queerdoc]: QueerDoc, “Legal Challenges To Trump Administration Attacks on Youth Gender Care (2025),” Oct. 14, 2025, https://queerdoc.com/the-legal-fights-against-the-trump-administration/  \n\n[^lambda]: Lambda Legal, “Federal Court Blocks Trump Anti-Equity and Anti-Transgender Executive Orders Targeting LGBTQ and HIV-Serving Nonprofits,” June 9, 2025, https://lambdalegal.org/newsroom/sfaf_us_20250609_federal-court-blocks-trump-anti-equity-and-anti-transgender-executive-orders-targeting-lgbtq-and-hiv-serving-nonprofits  \n\n[^williams]: Williams Institute, “Impact of US Refugee Admissions Overhaul on LGBTQI+ Refugees,” Oct. 2025, esp. discussion of 7,500 cap and preference for white Afrikaner refugees, https://williamsinstitute.law.ucla.edu/publications/refugee-cap-impact-lgbtqi/  \n\n[^nafsa]: NAFSA, “Executive and Regulatory Actions Under the Second Trump Administration” (birthright citizenship EO; ‘extreme vetting’ EO; expansion of expedited removal), https://www.nafsa.org/executive-and-regulatory-actions-trump2admin  \n\n[^unzueta]: Unzueta Law, “2025 Asylum Policy Changes: Impacts, Risks, and Guidance,” Sept. 28, 2025 (summarizing Proclamation 10888 suspending asylum between ports of entry and new hurdles), https://www.unzuetalaw.com/blog/2025-asylum-policy-changes-impacts-risks-and-guidance  \n\n[^immeq-trapped]: Immigration Equality et al., “Trapped in Danger: Trump Administration Policies Endanger Persecuted LGBTQI+ People,” June 5, 2025, https://immigrationequality.org/press/press-releases-2/new-summary-report-details-how-trump-administration-policies-endanger-lgbtqi-people-at-risk-of-persecution/  \n\n[^brennan]: Brennan Center for Justice, “Rolling Back the Post-9/11 Surveillance State,” analysis of suspicionless surveillance and abuses, https://www.brennancenter.org/our-work/analysis-opinion/rolling-back-post-911-surveillance-state  \n\n[^aclu-surv]: ACLU, “Trump on Surveillance, Protest, and Free Speech,” outlining how a second Trump administration could weaponize surveillance powers, https://www.aclu.org/trump-on-surveillance-protest-and-free-speech  \n\n[^civicus]: CIVICUS Monitor, “USA Watchlist 2025 – Trump administration puts US civic freedoms under severe threat,” Mar. 10, 2025, https://monitor.civicus.org/watchlist-march-2025/USA/  \n\n[^rsf]: Reporters Without Borders, “USA: Trump cuts public media, uses taxpayer funds for propaganda instead,” May 2025, https://rsf.org/en/usa-trump-cuts-public-media-uses-taxpayer-funds-propaganda-instead  \n\n[^nbc]: NBC News, “Trump is reversing the Justice Department’s civil rights policies,” 2025, https://www.nbcnews.com/politics/justice-department/trump-reversing-justice-departments-civil-rights-policies-rcna189657  \n\n[^aclu-p2025]: ACLU, “Project 2025, Explained,” 2024, https://www.aclu.org/project-2025-explained\n\nDoc B (id=B):\n## [Official Title]\n\nExecutive Order 14273 — “Lowering Drug Prices by Once Again Putting Americans First”\n\n---\n\n## Table of Contents\n\n1. [Official Title]  \n2. Table of Contents  \n3. [Descriptive Title]  \n4. What the EO Does  \n5. Stated Purpose & Justification  \n6. Nefarious Reality & True Impact  \n7. Connection to Broader Agenda  \n8. Harm Assessment  \n9. Reversal Strategy  \n\n---\n\n## [Descriptive Title]\n\nA Pharma-Friendly Rewrite of Drug “Negotiation” and a Trojan Horse Against the Inflation Reduction Act\n\n---\n\n## What the EO Does\n\nFactual summary of the order’s directives (with intentionally sharp characterization, but accurate to the text):\n\n- **Reframes federal drug policy around an attack on the Inflation Reduction Act (IRA):** Declares that Biden’s “misnamed Inflation Reduction Act” and its Medicare Drug Price Negotiation Program are administratively “complex,” too costly, and responsible for higher Part D premiums and reduced plan choice.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\n- **Directs HHS to rewrite core guidance for Medicare’s negotiation program:** Orders the Secretary of Health and Human Services (HHS) to issue new guidance for the Medicare Drug Price Negotiation Program covering 2026–2028 that “prioritizes” high-cost drugs but explicitly instructs the agency to “minimize any negative impacts” of lower prices on pharmaceutical “innovation.”([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\n- **Seeks to eliminate the IRA’s earlier negotiation of small‑molecule drugs (“pill penalty”):** Commands HHS to work with Congress to change the IRA so that small‑molecule drugs (pills) get the same, much longer, negotiation‑free window as biologics — moving from 9 to 13 years before Medicare can negotiate — under the banner of “ending distortion” in investment.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\n- **Initiates new payment models for high‑cost Medicare drugs:** Orders HHS to design and test a payment model that purports to obtain “better value” for high‑cost drugs and biologics, including ones not subject to negotiation, thereby opening a path to carve‑outs and side‑deals for the costliest products.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\n- **Re‑benchmarks Medicare outpatient drug payments to acquisition cost:** Requires HHS to survey hospital acquisition costs for outpatient drugs and consider revising payment rates to match those costs, within budget neutrality constraints.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\n- **Launches a Medicaid drug‑payment “innovation” review:** Instructs OMB and White House domestic and economic policy staff to recommend ways to “link payments to value” and “ensure accurate rebates,” pre‑staging more aggressive utilization controls and potentially narrower coverage in Medicaid.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\n- **Conditions community health center grants on restricted insulin/epinephrine pricing:** Directs HHS to require federally funded health centers to provide insulin and injectable epinephrine at or below their 340B acquisition price (plus a small fee) for low‑income or uninsured patients as a condition of receiving future grants.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\n- **Targets pharmacy benefit managers (PBMs) and employer plans:** Tells the Labor Department to draft regulations forcing PBMs to disclose compensation to employer health plans and orders White House staff to recommend broader PBM and supply‑chain reforms.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\n- **Pushes FDA to accelerate generics, biosimilars, and OTC switches:** Directs FDA to recommend ways to speed approval of generics and biosimilars and to reclassify some prescription drugs as over‑the‑counter products.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\n- **Expands state‑level drug importation:** Orders FDA to streamline Section 804 importation programs so states can more easily import drugs from abroad, “without sacrificing safety or quality.”([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\n- **Prepares an antitrust/competition report on pharma:** Instructs HHS, DOJ, Commerce, and the FTC to hold joint listening sessions on anti‑competitive drug‑maker conduct and deliver a report — which is then explicitly incorporated into Trump’s separate “Most‑Favored‑Nation” EO as a trigger for enforcement campaigns.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\n---\n\n## Stated Purpose & Justification\n\nIn Trump’s telling, EO 14273 is a heroic restoration of his first‑term “America First” drug agenda, sabotaged by Biden and the IRA, and now resurrected in purer form.\n\nKey elements of the official rationale:\n\n- **Self‑congratulation for first‑term drug orders:** The order opens by recounting an array of 2017–2020 initiatives — promoting generics and biosimilars, allowing limited importation, mandating rebate pass‑throughs, and capping insulin copays for Medicare beneficiaries — as “some of the most aggressive in recent history” to lower prices.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\n- **Blaming Biden and the IRA:** Section 1 asserts that the Biden administration “reversed, walked back, or neglected” these efforts and that the “misnamed” Inflation Reduction Act’s negotiation program is so complex and expensive that it has produced “much lower savings than projected,” while allegedly inflating Part D premiums and forcing a “taxpayer‑funded bailout” of insurers.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\n- **The “pill penalty” narrative:** The EO frames the IRA’s earlier negotiation of small‑molecule drugs (price controls 4 years sooner than for biologics) as a “pill penalty” that will shift R&D away from cheap pills toward exotic biologics and rare‑disease drugs, supposedly hurting patients who rely on common oral medications.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\n- **Promise to “restore progress” and put “Americans first”:** Trump claims that undoing Biden’s changes and altering the IRA will “restore the progress” of his first term and “dramatically narrow the price disparity” between the U.S. and other rich countries, portraying the order as a populist corrective to both Big Pharma and foreign “freeloaders.”([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))\n\nMeasured against independent evidence, this story is deeply misleading. KFF’s analysis of the IRA projects nearly $100 billion in Medicare savings over 10 years from drug negotiation provisions alone, with only modest effects on innovation.([kff.org](https://www.kff.org/medicare/issue-brief/explaining-the-prescription-drug-provisions-in-the-inflation-reduction-act/?utm_source=openai)) CMS data show the initial round of IRA negotiations under Biden will save about $6 billion (22%) on just 10 drugs starting in 2026,([cms.gov](https://www.cms.gov/newsroom/press-releases/negotiating-lower-drug-prices-works-saves-billions?utm_source=openai)) and Trump’s own CMS is now bragging that the second round of negotiations for 15 high‑cost drugs will save an additional ~$8–12 billion and cut prices by up to 71%.([washingtonpost.com](https://www.washingtonpost.com/health/2025/11/26/trump-medicare-drug-prices-ozempic/?utm_source=openai))\n\nIn other words, the empirical record flatly contradicts the EO’s claim that the IRA negotiation framework “has thus far produced much lower savings than projected.” The order’s “justification” functions more as a political indictment of a Democratic law than a truthful assessment of policy performance.\n\n---\n\n## Nefarious Reality & True Impact\n\n### 1. A structural bailout for Big Pharma, wrapped in populist rhetoric\n\nThe most consequential move in EO 14273 is its assault on the IRA’s differential treatment of small‑molecule drugs versus biologics. The IRA allows Medicare to negotiate prices 9 years after approval for small‑molecule drugs, but only after 13 years for biologics.([cnbc.com](https://www.cnbc.com/2025/04/22/healthy-returns-trump-seeks-to-change-medicare-drug-price-negotiations.html?utm_source=openai))\n\nTrump’s EO instructs HHS to work with Congress to “align” these timelines — i.e., **delay negotiation for pills by four extra years**, matching biologics.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/)) Independent health‑policy analysis (KFF, among others) has been blunt: eliminating the “pill penalty” would keep small‑molecule blockbusters at monopoly‑level prices longer, **raising Medicare spending, drug prices, and Part D premiums** relative to baseline IRA implementation.([cnbc.com](https://www.cnbc.com/2025/04/22/healthy-returns-trump-seeks-to-change-medicare-drug-price-negotiations.html?utm_source=openai))\n\nReuters reporting makes clear how eagerly the industry embraced this change: the EO is described as a “win for pharma companies” because it backs their demand to extend the no‑negotiation window for pills from 9 to 13 years, aligning with biotech drugs.([reuters.com](https://www.reuters.com/world/us/trump-signs-healthcare-executive-order-that-includes-win-pharma-companies-2025-04-15/?utm_source=openai)) The later “One Big Beautiful Bill Act” then codifies additional negotiation exemptions and delays for blockbuster drugs like Keytruda and Darzalex, with CBO estimating several billion dollars in lost Medicare savings over a decade.([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-congressional-budget-office-lifts-orphan-drug-cost-estimate-88-billion-2025-10-20/?utm_source=openai))\n\n**Bottom line:** the EO’s core structural change is a deliberate loosening of the IRA’s grip on drug prices — a massive, slow‑burn transfer of income from patients and taxpayers to pharmaceutical shareholders, cynically packaged as consumer protection.\n\n### 2. Weaponizing executive power against a duly enacted statute\n\nEO 14273 doesn’t just complain about the IRA; it **tries to re‑write it from the West Wing**:\n\n- It orders HHS to issue new negotiation guidance that explicitly balances lower prices against “negative impacts” on innovation — code for softening discounts and narrowing the set of drugs aggressively targeted.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))  \n- It centralizes control in the White House (Assistant to the President for Domestic Policy, OMB Director, Assistant for Economic Policy) to shape premiums, Medicaid “value‑based” payment, and PBM regulation — areas where Congress set broad guardrails via statute.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))  \n\nThis is a textbook example of **executive overreach**: an EO attempting to reinterpret and politically neuter a major congressional reform (the IRA) without going back to Congress for repeal. Later, the administration *does* go to Congress for the more lucrative giveaways (e.g., orphan‑drug and small‑molecule carve‑outs in the “Big Beautiful Bill”), but EO 14273 is the initial administrative battering ram.\n\n### 3. Coupling EO 14273 to a coercive “Most‑Favored‑Nation” regime\n\nEO 14273’s Section 13 instructs HHS to coordinate with DOJ, Commerce, and the FTC to identify “anti‑competitive behavior” by drug manufacturers. That report is then explicitly wired into Trump’s May 12, 2025 “Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients” order, which authorizes aggressive trade, antitrust, and regulatory retaliation if manufacturers don’t accept U.S. prices pegged to the lowest among rich countries.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/05/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients/))\n\nOn the surface, MFN pricing looks populist: tie U.S. prices to those in other wealthy countries that pay far less. But legal and policy analysis notes that:\n\n- Implementation is legally and administratively fraught, likely requiring new regulations and inviting industry litigation (as in Trump’s first‑term MFN attempt).([cnbc.com](https://www.cnbc.com/2025/05/12/trump-most-favored-nations-drug-price-order-what-to-know.html?utm_source=openai))  \n- Pharma can defend its profits by **raising prices abroad** rather than accepting deep U.S. cuts, exporting American‑style high prices to the rest of the world and undermining global health equity.([petrieflom.law.harvard.edu](https://petrieflom.law.harvard.edu/2025/05/22/the-global-risks-of-americas-most-favored-nation-drug-pricing-policy/?utm_source=openai))  \n- MFN does nothing to dismantle the patent‑evergreening and monopoly‑extension tactics that are the real engine of U.S. drug price inflation.([petrieflom.law.harvard.edu](https://petrieflom.law.harvard.edu/2025/05/22/the-global-risks-of-americas-most-favored-nation-drug-pricing-policy/?utm_source=openai))  \n\nIn practice, EO 14273 plus the MFN EO construct a **nationalist cartel strategy**: threaten foreign countries and regulators so that global prices converge *upward* while simultaneously delaying negotiation at home for a large class of drugs.\n\n### 4. Strategic tokenism toward patients to disguise structural sabotage\n\nEO 14273 is not a pure corporate giveaway. It contains a handful of visibly patient‑friendly measures:  \n\n- Binding community health centers to pass through 340B discounts on insulin and epinephrine to low‑income patients;  \n- Demanding more PBM fee transparency for employer plans;  \n- Asking FDA to speed generics, biosimilars, and some OTC switches;  \n- Facilitating importation pilot programs for states.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))  \n\nSome of these may yield **real, if modest, relief**. But they are carefully chosen low‑hanging fruit: reforms that do not seriously threaten industry profit margins and are politically difficult for critics to oppose.\n\nAgainst this backdrop, the structural changes — pill‑penalty repeal, negotiation guidance tilted towards “innovation,” legislative efforts to exempt or delay high‑revenue drugs from negotiation — dwarf the token benefits. CBO’s estimate that IRA drug pricing will save Medicare ~$98.5 billion over a decade, and CMS’s own documentation of billions already saved, show the magnitude of what’s at stake.([kff.org](https://www.kff.org/medicare/issue-brief/explaining-the-prescription-drug-provisions-in-the-inflation-reduction-act/?utm_source=openai)) EO 14273’s architecture is about *clawing back* those public savings in the name of corporate “incentives.”\n\n---\n\n## Connection to Broader Agenda\n\nEO 14273 is not an isolated technocratic tweak; it is a pillar of the administration’s broader authoritarian‑nationalist project.\n\n1. **Undermining Democratic Governance of Health Policy**\n\n   - The IRA’s drug provisions were enacted through a hard‑fought democratic process; Trump’s EO seeks to hollow them out through executive fiat and back‑channel guidance.  \n   - Centralizing key decisions (negotiation strategy, Medicaid “value” frameworks, PBM oversight) in the White House staff rather than transparent agency rulemaking entrenches a **personalized presidency** that treats legislation as a suggestion, not a binding framework.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))  \n\n2. **Nationalist Scapegoating and Trade Aggression**\n\n   - The MFN architecture, explicitly linked back to EO 14273, is framed as punishing “global freeloading” and “socialist countries” that demand low drug prices — deliberately stoking resentment against foreign publics and multilateral norms.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/05/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients/?utm_source=openai))  \n   - This rhetoric dovetails with Trump’s broader foreign‑policy posture: weaponizing trade and regulation to extract concessions without international coordination, weakening cooperative mechanisms that could genuinely reduce global drug prices and expand access.\n\n3. **Plutocratic Entrenchment Behind Populist Slogans**\n\n   - Simultaneously, the administration pushes major legislative changes (e.g., the “One Big Beautiful Bill Act”) that hard‑wire new exceptions and delays into the IRA’s negotiation scheme, heavily lobbied for by the pharmaceutical industry and projected by CBO to raise federal outlays by billions.([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-congressional-budget-office-lifts-orphan-drug-cost-estimate-88-billion-2025-10-20/?utm_source=openai))  \n   - Trump touts fantastical claims of cutting drug prices by “up to 1,500%,” which fact‑checkers note is mathematically impossible, illustrating the propaganda function of these orders: bold, easily debunked boasts that saturate the information space and numb accountability.([apnews.com](https://apnews.com/article/b3e5bf8a98310de45e39d3911d112979?utm_source=openai))  \n\nTaken together, EO 14273 is part of a **systemic project of authoritarian clientelism**: consolidate power in the executive, reward strategic corporate allies, scapegoat external enemies (Democrats, foreigners, “bureaucrats”), and use a few headline‑grabbing deals to obscure the quiet dismantling of a democratically enacted affordability regime.\n\n---\n\n## Harm Assessment\n\n### 1. Seniors and Disabled People on Medicare\n\n**Short‑term:**  \n- IRA negotiations — which Trump inherited — are already lowering prices for high‑cost drugs. The first Biden‑era round (10 drugs) would have saved $6 billion,([cms.gov](https://www.cms.gov/newsroom/press-releases/negotiating-lower-drug-prices-works-saves-billions?utm_source=openai)) and Trump’s CMS now touts roughly $8–12 billion of additional savings from the second round (15 drugs, including Ozempic and Wegovy), with price cuts up to 71%.([washingtonpost.com](https://www.washingtonpost.com/health/2025/11/26/trump-medicare-drug-prices-ozempic/?utm_source=openai))  \n\n**Medium‑to‑long term under EO 14273 trajectory:**\n\n- By pushing to extend the no‑negotiation period for small‑molecule drugs from 9 to 13 years — and championing legislation that grants more exemptions — the administration dramatically **erodes future savings**, especially on widely used pills that dominate Medicare spending. Analysts warn that eliminating the pill penalty would mean higher Medicare drug spending and steeper Part D premiums than under the baseline IRA.([cnbc.com](https://www.cnbc.com/2025/04/22/healthy-returns-trump-seeks-to-change-medicare-drug-price-negotiations.html?utm_source=openai))  \n- CBO’s updated scoring of Trump‑backed exemptions indicates at least $6–10+ billion in additional federal costs over a decade, directly undermining the IRA’s $98.5 billion in projected savings.([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-congressional-budget-office-lifts-orphan-drug-cost-estimate-88-billion-2025-10-20/?utm_source=openai))  \n\n**Net effect:** Seniors get a tranche of short‑term, well‑publicized price reductions (mostly attributable to the IRA framework) while long‑run affordability and program sustainability are sacrificed to industry demands.\n\n### 2. Low‑Income People and Medicaid Beneficiaries\n\n- MFN deals with Pfizer, AstraZeneca, Eli Lilly, and Novo Nordisk purport to offer Medicaid programs “most‑favored‑nation” pricing for their products, producing “hundreds of millions” in savings and expanded access to high‑profile drugs like GLP‑1s for diabetes and obesity.([whitehouse.gov](https://www.whitehouse.gov/fact-sheets/2025/10/fact-sheet-president-donald-j-trump-announces-second-deal-to-bring-most-favored-nation-pricing-to-american-patients/?utm_source=openai))  \n- But these deals are private, company‑specific, and heavily conditioned on trade concessions and revenue‑repatriation commitments — not structural reforms. Pharma stock price increases after MFN announcements signal that investors do not expect profit carnage; the burden is likely shifted geographically or temporally, not eliminated.([cnbc.com](https://www.cnbc.com/2025/05/12/trump-drug-pricing-order-most-favored-nation.html?utm_source=openai))  \n\nAt the same time, “value‑based” Medicaid payment and new utilization controls, framed as innovation‑friendly, risk **tightening access** for people whose lives are already precarious, embedding more gatekeeping and bureaucratic discretion into coverage decisions.\n\n### 3. Global Public Health and International Equity\n\nHarvard’s Petrie‑Flom Center and others warn that MFN pricing, especially when tethered to aggressive trade threats, will likely **push drug companies to raise prices in countries that currently secure lower costs** — particularly in Europe and parts of the Global South — to preserve profit margins.([petrieflom.law.harvard.edu](https://petrieflom.law.harvard.edu/2025/05/22/the-global-risks-of-americas-most-favored-nation-drug-pricing-policy/?utm_source=openai))\n\n- This transforms U.S. “reform” into a **global shock‑therapy** for drug prices, exporting our dysfunctional pricing model abroad and undermining universal health systems.  \n- MFN also does nothing to address U.S. patent‑system abuses (evergreening, thickets) that drive high list prices, leaving domestic structural injustices untouched.([petrieflom.law.harvard.edu](https://petrieflom.law.harvard.edu/2025/05/22/the-global-risks-of-americas-most-favored-nation-drug-pricing-policy/?utm_source=openai))  \n\nThe EO therefore contributes to **worldwide rationing and suffering** while preserving the underlying mechanisms of monopoly power.\n\n### 4. Democratic Institutions and Policy Capacity\n\n- The EO’s effort to re‑write the IRA via executive guidance normalizes a model where **any major statute can be gutted by hostile administrations** without formal repeal, corroding the meaning of legislative victory and degrading trust in democratic policymaking.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))  \n- The fusion of trade, antitrust, and drug policy under MFN and its reliance on presidential discretion (e.g., when to declare foreign policies “unreasonable”) further concentrates power in the executive, weakening independent agencies and rule‑bound processes.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/05/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients/))  \n\n---\n\n## Reversal Strategy\n\nThree concrete actions for a future administration to undo EO 14273’s damage and reclaim democratic, pro‑patient drug policy:\n\n1. **Immediate Revocation of EO 14273 and Its MFN Linkages**  \n   - Repeal EO 14273 and the May 12, 2025 MFN order on Day One; direct HHS, CMS, FDA, DOJ, and FTC to withdraw or supersede all guidance and rulemaking premised on these orders and restore IRA‑consistent negotiation guidance that maximizes savings and access rather than “minimizing impacts” on innovation.([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/))  \n\n2. **Legislative Re‑Anchoring of the IRA’s Negotiation Framework**  \n   - Pass corrective legislation that: (a) re‑locks the 9‑year/13‑year small‑molecule/biologic negotiation timelines; (b) repeals the “Big Beautiful Bill” exemptions and any pill‑penalty repeals; and (c) codifies restrictions on future executive guidance that would undercut statutory negotiation objectives, drawing on KFF and CBO evidence about the IRA’s savings and limited innovation impacts.([kff.org](https://www.kff.org/medicare/issue-brief/explaining-the-prescription-drug-provisions-in-the-inflation-reduction-act/?utm_source=openai))  \n\n3. **Structural Reform of Drug Pricing and Global Solidarity Mechanisms**  \n   - Use the IRA’s existing authority as a foundation to: (a) clamp down on evergreening and patent abuse; (b) expand and speed biosimilar and generic competition; and (c) build multilateral agreements with other high‑income and middle‑income countries on joint negotiation and R&D financing, replacing MFN’s unilateral trade threats with cooperative price‑setting that lowers prices **everywhere** rather than exporting U.S. price inflation.([cms.gov](https://www.cms.gov/newsroom/press-releases/negotiating-lower-drug-prices-works-saves-billions?utm_source=openai))  \n\nThese steps would not only reverse the damage from EO 14273 but also push U.S. drug policy toward a genuinely egalitarian, democracy‑affirming regime — one that treats medicines as public goods, not bargaining chips in a nationalist protection racket.\n\n\nPairwise evaluation payload placeholder."
      }
    ],
    "max_output_tokens": 50000,
    "tools": [
      {
        "type": "web_search",
        "search_context_size": "medium"
      }
    ],
    "tool_choice": "auto",
    "reasoning": {
      "effort": "high"
    },
    "text": {
      "format": {
        "type": "json_schema",
        "name": "evaluation_result",
        "schema": {
          "type": "object",
          "properties": {
            "evaluations": {
              "type": "array",
              "items": {
                "type": "object",
                "properties": {
                  "criterion": {
                    "type": "string"
                  },
                  "score": {
                    "type": "integer"
                  },
                  "reason": {
                    "type": "string"
                  }
                },
                "required": [
                  "criterion",
                  "score",
                  "reason"
                ],
                "additionalProperties": true
              }
            },
            "winner_doc_id": {
              "type": "string"
            },
            "reason": {
              "type": "string"
            }
          },
          "additionalProperties": true
        },
        "strict": false
      }
    }
  },
  "response": {
    "id": "resp_090810aaa12aaadc00692bdf07332481979942af199af29bd7",
    "object": "response",
    "created_at": 1764482823,
    "status": "completed",
    "background": false,
    "billing": {
      "payer": "developer"
    },
    "error": null,
    "incomplete_details": null,
    "instructions": null,
    "max_output_tokens": 50000,
    "max_tool_calls": null,
    "model": "gpt-5.1-2025-11-13",
    "output": [
      {
        "id": "rs_090810aaa12aaadc00692bdf07efc48197bff12bb4afb9467f",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf169b688197bb15cb44552af218",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"Executive Order 14273\" \"Lowering Drug Prices by Once Again Putting Americans First\""
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf1919c88197bb56b0e1ec2ab9a4",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf1ae0ec819784ddf001ceb8ef6d",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"Executive Order 14273\" gender affirming care"
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf1cfa2881979f739b46e5512992",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf1e43c48197983335aad6fc818e",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search"
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf1f68948197958aa1e5f98bf135",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf21c7b88197bfbf99516d11a58f",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"Executive Order 14273\" Trump \"Denial of Care\""
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf2370048197b5b5a1c1f899fc8c",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf2541dc8197b26b6fbe71311375",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search"
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf2776188197be274fa2f497eb14",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf2a3d18819791f347bae9cdf847",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"Families and Advocates Sue Trump Administration Over Executive Order\" \"restrict access to gender-affirming care\" Feb. 4, 2025"
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf2d46fc81978ed97f7b051a1b8c",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf33ec9081978c9310f67a5a3832",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"Presidential Determination 2025-13\" refugee cap 7,500 Afrikaner"
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf35ed148197a4afdde7bccc4f64",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf42cec08197a9317179395294f0",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "KFF explaining the prescription drug provisions in the Inflation Reduction Act $98.5 billion savings over 10 years drug negotiation"
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf45caac819782f79254a8d348dd",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf45fcf48197ab616d5e94caa9c9",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search"
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf47eff48197b76dff47ebb2a16b",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf4887b08197aebefdcbde98dd69",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search"
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf4c80a08197a5bc10d5596c1b1a",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf578b888197b1092542a50a5596",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"1,500%\" \"Trump\" \"drug prices\""
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf5c8f00819785653e451acaec0a",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf5fd07c81979a1b46a3b2ecba66",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"One Big Beautiful Bill Act\" drug negotiation orphan 2025 CBO"
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf63d9e88197977b5acd11f0c0d0",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf67f46c8197b860503d951887bd",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "QueerDoc \"Legal Fights Against the Trump Administration\" youth gender care 2025"
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf6fc08881979b5eb1139ba62ac1",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf744878819797957bb4219743a4",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search"
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf76d3188197ab6284d89e7221da",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf77690c819785de33e17177e6e6",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"global risks\" \"most favored nation\" drug pricing policy Petrie-Flom"
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf7bf3a881979678a8d540841ed7",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf7c918c819784153be3ac7c9f9c",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search"
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf7ee29c819799e15594cb0d1da9",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf804b1481979fe78d8133819c10",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"Trump signs healthcare executive order that includes win pharma companies\" April 15 2025"
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf8571448197904178ac507f5180",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "ws_090810aaa12aaadc00692bdf8fb25c8197aaf416e806ea388f",
        "type": "web_search_call",
        "status": "completed",
        "action": {
          "type": "search",
          "query": "\"Fact Sheet: President Donald J. Trump Announces Second Deal to Bring Most-Favored-Nation Pricing to American Patients\""
        }
      },
      {
        "id": "rs_090810aaa12aaadc00692bdf932e7c8197978a6e2cb06c2db1",
        "type": "reasoning",
        "summary": []
      },
      {
        "id": "msg_090810aaa12aaadc00692bdfc6c70081978de2a1188ecfe3b4",
        "type": "message",
        "status": "completed",
        "content": [
          {
            "type": "output_text",
            "annotations": [],
            "logprobs": [],
            "text": "{\"evaluations\":[{\"criterion\":\"factuality_eo_alignment_DocA\",\"score\":1,\"reason\":\"Doc A repeatedly attributes provisions to EO 14273 that do not exist in the official text or credible summaries—such as conditioning formularies on bans of gender‑affirming care and abortion, attaching ideological riders to immigrant/refugee drug coverage, and creating DHS/DOJ/Treasury health‑data sharing mandates—none of which appear anywhere in EO 14273 or in documented implementation, indicating major hallucinations.\"},{\"criterion\":\"factuality_eo_alignment_DocB\",\"score\":5,\"reason\":\"Doc B’s description of EO 14273 closely tracks the official order and primary analyses: it accurately reports the IRA “pill penalty” change (aligning small‑molecule and biologic negotiation timelines), the negotiation‑guidance rewrite to prioritize high‑cost drugs while minimizing impacts on “innovation,” new Medicare payment models, community health center insulin/epinephrine pricing conditions, PBM disclosure rules, FDA directions on generics/OTC switches, importation streamlining, and Section 13’s competition report that is explicitly referenced in the later MFN EO.\"},{\"criterion\":\"overall_assessment\",\"score\":5,\"reason\":\"Because Doc A’s core account of what EO 14273 does is factually wrong while Doc B is tightly grounded in the EO text and high‑quality sources yet still offers strong left‑critical, anti‑authoritarian analysis, Doc B is decisively superior on factuality, source quality, structure, and instruction adherence.\"}],\"winner_doc_id\":\"B\",\"reason\":\"Doc B wins because it is tightly grounded in the actual text and documented effects of EO 14273, while Doc A fabricates key provisions (ideological conditions on drug coverage, immigration‑linked riders, and sweeping data‑sharing schemes) that do not exist in the real order, violating the no‑hallucination standard.\"}"
          }
        ],
        "role": "assistant"
      }
    ],
    "parallel_tool_calls": true,
    "previous_response_id": null,
    "prompt_cache_key": null,
    "prompt_cache_retention": null,
    "reasoning": {
      "effort": "high",
      "summary": null
    },
    "safety_identifier": null,
    "service_tier": "default",
    "store": true,
    "temperature": 1.0,
    "text": {
      "format": {
        "type": "json_schema",
        "description": null,
        "name": "evaluation_result",
        "schema": {
          "type": "object",
          "properties": {
            "evaluations": {
              "type": "array",
              "items": {
                "type": "object",
                "properties": {
                  "criterion": {
                    "type": "string"
                  },
                  "score": {
                    "type": "integer"
                  },
                  "reason": {
                    "type": "string"
                  }
                },
                "required": [
                  "criterion",
                  "score",
                  "reason"
                ],
                "additionalProperties": true
              }
            },
            "winner_doc_id": {
              "type": "string"
            },
            "reason": {
              "type": "string"
            }
          },
          "additionalProperties": true
        },
        "strict": false
      },
      "verbosity": "medium"
    },
    "tool_choice": "auto",
    "tools": [
      {
        "type": "web_search",
        "filters": null,
        "search_context_size": "medium",
        "user_location": {
          "type": "approximate",
          "city": null,
          "country": "US",
          "region": null,
          "timezone": null
        }
      }
    ],
    "top_logprobs": 0,
    "top_p": 1.0,
    "truncation": "disabled",
    "usage": {
      "input_tokens": 92160,
      "input_tokens_details": {
        "cached_tokens": 10880
      },
      "output_tokens": 11839,
      "output_tokens_details": {
        "reasoning_tokens": 11434
      },
      "total_tokens": 103999
    },
    "user": null,
    "metadata": {}
  },
  "web_search": [
    {
      "id": "ws_090810aaa12aaadc00692bdf169b688197bb15cb44552af218",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Executive Order 14273\" \"Lowering Drug Prices by Once Again Putting Americans First\""
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf1ae0ec819784ddf001ceb8ef6d",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Executive Order 14273\" gender affirming care"
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf1e43c48197983335aad6fc818e",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search"
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf21c7b88197bfbf99516d11a58f",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Executive Order 14273\" Trump \"Denial of Care\""
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf2541dc8197b26b6fbe71311375",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search"
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf2a3d18819791f347bae9cdf847",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Families and Advocates Sue Trump Administration Over Executive Order\" \"restrict access to gender-affirming care\" Feb. 4, 2025"
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf33ec9081978c9310f67a5a3832",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Presidential Determination 2025-13\" refugee cap 7,500 Afrikaner"
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf42cec08197a9317179395294f0",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "KFF explaining the prescription drug provisions in the Inflation Reduction Act $98.5 billion savings over 10 years drug negotiation"
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf45fcf48197ab616d5e94caa9c9",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search"
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf4887b08197aebefdcbde98dd69",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search"
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf578b888197b1092542a50a5596",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"1,500%\" \"Trump\" \"drug prices\""
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf5fd07c81979a1b46a3b2ecba66",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"One Big Beautiful Bill Act\" drug negotiation orphan 2025 CBO"
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf67f46c8197b860503d951887bd",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "QueerDoc \"Legal Fights Against the Trump Administration\" youth gender care 2025"
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf744878819797957bb4219743a4",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search"
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf77690c819785de33e17177e6e6",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"global risks\" \"most favored nation\" drug pricing policy Petrie-Flom"
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf7c918c819784153be3ac7c9f9c",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search"
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf804b1481979fe78d8133819c10",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Trump signs healthcare executive order that includes win pharma companies\" April 15 2025"
      }
    },
    {
      "id": "ws_090810aaa12aaadc00692bdf8fb25c8197aaf416e806ea388f",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Fact Sheet: President Donald J. Trump Announces Second Deal to Bring Most-Favored-Nation Pricing to American Patients\""
      }
    }
  ],
  "reasoning": "high",
  "human_text": "{\"evaluations\":[{\"criterion\":\"factuality_eo_alignment_DocA\",\"score\":1,\"reason\":\"Doc A repeatedly attributes provisions to EO 14273 that do not exist in the official text or credible summaries—such as conditioning formularies on bans of gender‑affirming care and abortion, attaching ideological riders to immigrant/refugee drug coverage, and creating DHS/DOJ/Treasury health‑data sharing mandates—none of which appear anywhere in EO 14273 or in documented implementation, indicating major hallucinations.\"},{\"criterion\":\"factuality_eo_alignment_DocB\",\"score\":5,\"reason\":\"Doc B’s description of EO 14273 closely tracks the official order and primary analyses: it accurately reports the IRA “pill penalty” change (aligning small‑molecule and biologic negotiation timelines), the negotiation‑guidance rewrite to prioritize high‑cost drugs while minimizing impacts on “innovation,” new Medicare payment models, community health center insulin/epinephrine pricing conditions, PBM disclosure rules, FDA directions on generics/OTC switches, importation streamlining, and Section 13’s competition report that is explicitly referenced in the later MFN EO.\"},{\"criterion\":\"overall_assessment\",\"score\":5,\"reason\":\"Because Doc A’s core account of what EO 14273 does is factually wrong while Doc B is tightly grounded in the EO text and high‑quality sources yet still offers strong left‑critical, anti‑authoritarian analysis, Doc B is decisively superior on factuality, source quality, structure, and instruction adherence.\"}],\"winner_doc_id\":\"B\",\"reason\":\"Doc B wins because it is tightly grounded in the actual text and documented effects of EO 14273, while Doc A fabricates key provisions (ideological conditions on drug coverage, immigration‑linked riders, and sweeping data‑sharing schemes) that do not exist in the real order, violating the no‑hallucination standard.\"}",
  "usage": {
    "prompt_tokens": 92160,
    "completion_tokens": 11839,
    "total_tokens": 103999
  },
  "cost": {
    "input_price_per_million_usd": null,
    "output_price_per_million_usd": null,
    "input_tokens": 92160,
    "output_tokens": 11839,
    "input_cost_usd": null,
    "output_cost_usd": null,
    "total_cost_usd": null,
    "pricing_last_updated": null,
    "pricing_source": null,
    "pricing_source_url": null,
    "unit": null,
    "reason": "pricing_not_found"
  },
  "total_cost_usd": null
}